Bevacizumab/octreotideDiarrhoea, hypertension and epistaxis: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1792卷 / 1期

关键词：

D O I：

10.1007/s40278-020-75162-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：54 / 54

相关论文

共 50 条

[41] Bevacizumab/cyclophosphamideMucositis and intestinal fistula: 2 case reports
[J]. Reactions Weekly, 2011, 1339 (1) : 11 - 11
[42] Bevacizumab/denosumab/pemetrexedOsteonecrosis of the jaw: 2 case reports
[J]. Reactions Weekly, 2019, 1741 (1) : 58 - 58
[43] Bevacizumab/cisplatin/cyclophosphamideAsthenia and anaemia: 2 case reports
[J]. Reactions Weekly, 2014, 1488 (1) : 10 - 10
[44] Bevacizumab/temozolomideEpistaxis, haemorrhoids and paraesthesia: 2 case reports
[J]. Reactions Weekly, 2020, 1835 (1) : 76 - 76
[45] Bevacizumab/ranibizumab/verteporfinLack of efficacy: 2 case reports
[J]. Reactions Weekly, 2023, 1954 (1) : 119 - 119
[46] Bevacizumab/ranibizumabVitreomacular traction syndrome: 2 case reports
[J]. Reactions Weekly, 2019, 1784 (1) : 65 - 65
[47] Bevacizumab/lobaplatin/paclitaxelHypertension and thrombocytopenia: 2 case reports
[J]. Reactions Weekly, 2022, 1926 (1) : 135 - 135
[48] Bevacizumab/erlotinibSkin and subcutaneous tissue disorders, malaise and hypertension: 7 case reports
[J]. Reactions Weekly, 2018, 1733 (1) : 84 - 84
[49] Bevacizumab/corticosteroid/dexamethasoneLack of efficacy: 2 case reports
[J]. Reactions Weekly, 2022, 1912 (1) : 120 - 120
[50] Bevacizumab/erlotinibGastrointestinal perforation and rash: 2 case reports
[J]. Reactions Weekly, 2018, 1708 (1) : 80 - 80

← 1 2 3 4 5 →